SCHEMBL499046

SCHEMBL499046

CNCC(C)C(O)c1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 17/20 0.52
SLC6A4 P31645 17/20 0.52
SLC6A3 Q01959 15/20 0.48
CYP3A4 P08684 12/20 0.47
CYP2D6 P10635 12/20 0.47
KCNH2 Q12809 9/20 0.47
ADRB2 P07550 2/20 0.47
ADRB1 P08588 2/20 0.47
ADRB3 P13945 2/20 0.47
SLC2A1 P11166 1/20 0.46
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
TSHR P16473 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
NFKB1 P19838 1/20 0.45
DRD1 P21728 1/20 0.45
HTR7 P34969 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28951519 0.82 ACP3 (0.46) SLC6A2SLC6A4ADRB2ADRB1ADRB3
SCHEMBL3702012 0.81 ADRB1 (0.67) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6
SCHEMBL16679636 0.81 ADRB1 (0.67) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6
SCHEMBL16559342 0.79 SLC6A2 (0.60) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6
SCHEMBL29403128 0.76 ACP3 (0.50) SLC6A2SLC6A4ADRB2ADRB1ADRB3
SCHEMBL11606577 0.76 ACP3 (0.50) SLC6A2SLC6A4ADRB2ADRB1ADRB3
SCHEMBL16552498 0.75 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6
SCHEMBL16690960 0.75 SLC6A4 (0.49) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6
SCHEMBL9902866 0.75 SLC6A4 (0.49) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6
SCHEMBL634062 0.74 ADRB1 (0.42) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106221-B2 Renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-20100144825-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-06-10 US disclosed
WO-2008156816-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144825-A1 Renin Inhibitors ACE, REN, DNPEP SLC6A2 344/4885SLC6A4 603/4885SLC6A3 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.